Resources from the same session
35MO - Quality-adjusted survival in patients with advanced or recurrent endometrial carcinoma treated with atezolizumab in combination with carboplatin-paclitaxel versus carboplatin-paclitaxel in the AtTEnd/ENGOT-EN7 trial
Presenter: Maria Pilar Barretina Ginesta
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
36MO - Patient-reported outcomes in primary advanced or recurrent endometrial carcinoma treated with atezolizumab or placebo in combination with carboplatin-paclitaxel in the AtTEnd/ENGOT-EN7 trial
Presenter: Yeh Chen Lee
Session: Mini Oral session 1
Resources:
Abstract
37MO - Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: Overall survival (OS) by MMR status and molecular subgroups
Presenter: Robert Coleman
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
38MO - Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial
Presenter: Mansoor Raza Mirza
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
39MO - Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer
Presenter: Sandro Pignata
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
40MO - First-line (1L) durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib for endometrial cancer (EC) (DUO-E): Objective response rate (ORR), duration of response (DoR) and time to treatment discontinuation or death (TDT) by mismatch repair (MMR) status
Presenter: Els Van Nieuwenhuysen
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant abstracts 35MO+36MO, 37MO, 38MO, 39MO and 40MO
Presenter: Ramez Eskander
Session: Mini Oral session 1
Resources:
Slides
Webcast
82MO - European multi-disciplinary tumor boards within the EURACAN network increasingly support management of patients with rare gynaecological tumors: 6-year activity results
Presenter: Alice Bergamini
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
45MO - Management of stage I ovarian Sertoli-Leydig cell tumors: Prognostic factors from a multicenter international retrospective study
Presenter: Giovanna Scarfone
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant abstracts 82MO and 45MO
Presenter: Jubilee Brown
Session: Mini Oral session 1
Resources:
Slides
Webcast